TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17567417

Group type: EXPERIMENTAL
Intervention: New antenatal care model (five-visit model)
Number of subjects: 13517

Group type: COMPARATOR
Intervention: Standard antenatal care model
Number of subjects: 13517
Study: 15597183

Group type: EXPERIMENTAL
Intervention: Precue condition (arrows indicating target locations before the array)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simcue condition (arrows indicating target locations simultaneously with the array)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postcue condition (arrows indicating target locations after the array)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG potentials recorded during the experiment
Number of subjects: 0
Study: 11886903

Group type: EXPERIMENTAL
Intervention: Finger-trap traction
Number of subjects: 223

Group type: COMPARATOR
Intervention: Manual manipulation
Number of subjects: 223
Study: 9475655

Group type: EXPERIMENTAL
Intervention: Impact loading variables (three impact velocities and three interface materials)
Number of subjects: 19
Study: 8529329

Group type: EXPERIMENTAL
Intervention: Intravenous losartan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous EXP3174
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral losartan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral EXP3174
Number of subjects: 18
Study: 2193518

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pelvic examination
Number of subjects: 57
Study: 6305113

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation with a total dose of 25.5 Gy in fractions of 5.1 Gy daily for 5 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Retrospective data from 1976 to 1979 for patients operated upon for 'local cure'
Number of subjects: 58
Study: 30347485

Group type: EXPERIMENTAL
Intervention: Childhood overweight/obesity (Metabolic Groups III and IV)
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Normal body mass index in adulthood (after childhood overweight/obesity)
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Childhood normal body mass index (Metabolic Groups I and II)
Number of subjects: 2020
Study: 27822727

Group type: EXPERIMENTAL
Intervention: Handcrafted vacuum‐assisted therapy (changed every 72 hours)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Traditional treatment (debridement and cure with soap every 24 hours)
Number of subjects: 126
Study: 27711190

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 881
Study: 23932021

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 28 sessions at a partial pressure of oxygen of 240 kPa for 90 min
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 22
Study: 21748755

Group type: EXPERIMENTAL
Intervention: 5 or 25 mg of lenalidomide
Number of subjects: 0
Study: 19852807

Group type: COMPARATOR
Intervention: Normal gait (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diabetic gait (intervention group)
Number of subjects: 20
Study: 17606973

Group type: EXPERIMENTAL
Intervention: Ixabepilone 32 mg/m² 3-hour infusion (arm A)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Ixabepilone 6 mg/m² 1-hour infusion daily for 5 consecutive days (arm B)
Number of subjects: 146
Study: 16939989

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Inhaled corticosteroid add-on
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 49
Study: 12923800

Group type: EXPERIMENTAL
Intervention: Communication skills training course
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 160
Study: 10821130

Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus amlodipine (group II, n=13)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACE inhibitor alone (group I, n=17)
Number of subjects: 30
Study: 8604670

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 7
Study: 2004543

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2000 mg daily for 10 days
Number of subjects: 218
Study: 6824134

Group type: EXPERIMENTAL
Intervention: Autologous autotransfused blood
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bank blood
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Salvaged autologous blood
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (unshed autologous blood)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liver function values and free hemoglobin levels
Number of subjects: 50
Study: 29164599

Group type: EXPERIMENTAL
Intervention: JWH‐018 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: JWH‐018 3 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28790354

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 101
Study: 26136534

Group type: EXPERIMENTAL
Intervention: 30 g whey protein (PRO) postexercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA) postexercise
Number of subjects: 15
Study: 23032867

Group type: EXPERIMENTAL
Intervention: S‐ICD (subcutaneous implantable cardioverter-defibrillator)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional ICD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: S‐ICD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: S‐ICD and Conventional ICD
Number of subjects: 69
Study: 20500136

Group type: EXPERIMENTAL
Intervention: Behavioural graded activity
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 18476431

Group type: EXPERIMENTAL
Intervention: Kangyanling plus Omeprazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 52
Study: 15836974

Group type: EXPERIMENTAL
Intervention: Iyengar yoga therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 60
Study: 12900300

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study: 10526822

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study: 8867561

Group type: EXPERIMENTAL
Intervention: Study nurse measurements (22/14 +/- 20/9 mm Hg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Study doctor measurements (27/12 +/- 20/10 mm Hg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Referring doctor measurements (19/11 +/- 18/10 mm Hg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Older patients (>= 65 years)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Younger patients (< 65 years)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 64
Study: 1898686

Group type: EXPERIMENTAL
Intervention: Lower range of PaCO2 (32-48 mm Hg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Higher range of PaCO2 (50-71 mm Hg)
Number of subjects: 25
Study: 6688025

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Atracurium 0.8 mg kg‐1
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 96
Study: 30914216

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplement use
Number of subjects: 197761

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 197761
Study: 31089999

Group type: EXPERIMENTAL
Intervention: Formulated 11+ B. pyrrocinia × Magnaporthe oryzae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulated 32+ B. pyrrocinia × Magnaporthe oryzae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B. pyrrocinia × M. oryzae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulated 11 × M. oryzae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulated 32 × M. oryzae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M. oryzae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulated 11+ B. pyrrocinia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulated 32+ B. pyrrocinia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B. pyrrocinia
Number of subjects: 0
Study: 27839695

Group type: EXPERIMENTAL
Intervention: Educational session with attending orthopaedic surgeon
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Educational session with senior resident
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pre-educational session
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-educational session
Number of subjects: 13
Study: 26091325

Group type: EXPERIMENTAL
Intervention: Brief negotiated interview plus an educational kit by the American Automobile Association and a list of Web‐based resources for older adult drivers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: American Automobile Association document and a list of Web‐based resources
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Online referral sheet of the list of Web‐based resources only
Number of subjects: 120
Study: 22965330

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 134

Group type: COMPARATOR
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 134
Study: 21550532

Group type: EXPERIMENTAL
Intervention: Personal Nutrition Planner (PNP)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Comparison group (no program)
Number of subjects: 307
Study: 19549077

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (n = 40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 83
Study: 17805217

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15332578

Group type: EXPERIMENTAL
Intervention: Aspirin (250‐500 mg) + Clopidogrel (300 mg prehospital, then 75 mg/day after TLT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Aspirin (250‐500 mg)
Number of subjects: 72
Study: 10691156

Group type: EXPERIMENTAL
Intervention: Universal screening (50-g glucose challenge test followed by 3-h 100-g OGTT if plasma glucose at 1 h was >= 7.8 mmol/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk factor-based screening (3-h 100-g OGTT at 32 weeks if any risk factor for GDM was present)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal screening
Number of subjects: 0
Study: 9346458

Group type: EXPERIMENTAL
Intervention: Clinical practice guideline for low back pain and three bimonthly feedback reports on current use rates for lumbar spine imaging tests (x-rays, CT, MRI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no guideline or feedback reports)
Number of subjects: 95
Study: 1441870

Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (Group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bupivacaine + epinephrine (Group BE)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine (Group BC)
Number of subjects: 29
Study: 3556892

Group type: EXPERIMENTAL
Intervention: Educational intervention about otitis media
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 30240907

Group type: EXPERIMENTAL
Intervention: Different radioactive tracers and unilateral ligation of cervical lymph vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy (SEM) examination of lymphatic vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interstitial dye lymphography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double contrast injection in conjunctival lymphatics
Number of subjects: 0
Study: 29202568

Group type: EXPERIMENTAL
Intervention: Hybrid hyaluronic acid (two intrarticular injections)
Number of subjects: 48

Group type: COMPARATOR
Intervention: High molecular weight hyaluronic acid (two intrarticular injections)
Number of subjects: 48
Study: 26518870

Group type: EXPERIMENTAL
Intervention: HOCO-DHA (50 g/day) in muffins and cookies
Number of subjects: 35

Group type: COMPARATOR
Intervention: Barley flour (4.36 g/day of β-glucan) and control oil (50 g/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/day; DHA dosage 3 g/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: All-purpose flour and control oil (50 g/day)
Number of subjects: 35
Study: 23544862

Group type: EXPERIMENTAL
Intervention: Abnormal umbilical artery Doppler velocimetry
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fetal FVL carriership
Number of subjects: 54
Study: 21422865

Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery
Number of subjects: 0
Study: 19748675

Group type: EXPERIMENTAL
Intervention: VPDT + ITA (4 mg ITA injection)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VPDT alone (sham injection)
Number of subjects: 100
Study: 17761080

Group type: EXPERIMENTAL
Intervention: Cutting trocars (single or pyramidal bladed)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dilating trocars (radially or axially dilating)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radially dilating trocar
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All 4 disposable trocars (muscle cutting or dilating type)
Number of subjects: 56
Study: 15139789

Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron 0.25 mg
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron 0.75 mg
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron (0.25 or 0.75 mg)
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Intravenous ondansetron 32 mg
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Intravenous dolasetron 100 mg
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Intravenous dolasetron
Number of subjects: 1799
Study: 11489748

Group type: EXPERIMENTAL
Intervention: Low-dose 13-cis-retinoic acid
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Stage II HNSCC
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Stage I HNSCC
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Oral cavity site
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Stage II disease
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Stage I disease
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Overall smoking-related SPT development rates
Number of subjects: 1191
Study: 10204713

Group type: EXPERIMENTAL
Intervention: First degree relatives of M/TMD probands
Number of subjects: 224

Group type: COMPARATOR
Intervention: First degree relatives of controls
Number of subjects: 224
Study: 7719394

Group type: EXPERIMENTAL
Intervention: Diet and exercise program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 43
Study: 2292283

Group type: COMPARATOR
Intervention: Aspirin 1.2 g single dose
Number of subjects: 25

Group type: COMPARATOR
Intervention: Flurbiprofen 50 mg t.d.s. for three days
Number of subjects: 25
Study: 372266

Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active distraction group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perceived control group
Number of subjects: 80
Study: 31550958

Group type: EXPERIMENTAL
Intervention: Compound glycyrrhizin combined with fractional CO2 laser and triamcinolone acetonide solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractional CO2 laser and triamcinolone acetonide solution (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (including Control)
Number of subjects: 0
Study: 28847206

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg once daily
Number of subjects: 30449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30449

Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 30449

Group type: COMPARATOR
Intervention: Anacetrapib and Placebo
Number of subjects: 30449
Study: 24763358

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 8 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 77
Study: 23265982

Group type: EXPERIMENTAL
Intervention: High concentration of capsaicin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High concentration of menthol
Number of subjects: 17
Study: 21332817

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg per os daily (n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: TURP (n = 33)
Number of subjects: 66
Study: 19874160

Group type: EXPERIMENTAL
Intervention: Low baseline social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-treatment social support
Number of subjects: 0
Study: 16696911

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XFZYD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (regular therapy)
Number of subjects: 50
Study: 14566102

Group type: EXPERIMENTAL
Intervention: 125 mg of prednisolone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 250 mg of prednisolone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 10660503

Group type: EXPERIMENTAL
Intervention: Cefpirome 1 g
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g
Number of subjects: 42
Study: 9031407

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 55
Study: 1500478

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 70
Study: 6142467

Group type: EXPERIMENTAL
Intervention: 3.75 mg zopiclone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 40
Study: 2433653

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) given perioperatively and 3 and 6 months postoperatively at a dosage of 150 mg per course (total: 450 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage I
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage II
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage III
Number of subjects: 74
Study: 28840401

Group type: EXPERIMENTAL
Intervention: Rural adolescents
Number of subjects: 6316

Group type: EXPERIMENTAL
Intervention: Urban adolescents
Number of subjects: 6316

Group type: COMPARATOR
Intervention: Urban participants
Number of subjects: 6316

Group type: EXPERIMENTAL
Intervention: Rural participants
Number of subjects: 6316
Study: 26860055

Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (VRT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 24
Study: 24754065

Group type: EXPERIMENTAL
Intervention: Controlled exercise training (ET) for 6 weeks in Group S
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home exercise training (ET+) in Subgroup A (51 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home exercise training (ET-) in Subgroup B (46 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients in Group C who trained at home
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients in Group C who refused home ET
Number of subjects: 100
Study: 22851298

Group type: EXPERIMENTAL
Intervention: Intensified care and service during waiting time (100 minutes average waiting time)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular care (81 minutes average waiting time)
Number of subjects: 100
Study: 20467011

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g twice daily) with hypocaloric diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 16
Study: 18192785

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0
Study: 15914991

Group type: EXPERIMENTAL
Intervention: APF application followed by rinsing with water immediately after
Number of subjects: 0

Group type: COMPARATOR
Intervention: APF application followed by no rinsing or consuming of liquids or solids for 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APF application followed by washing with water jet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APF application followed by drinking a glass of water
Number of subjects: 0
Study: 12839527

Group type: EXPERIMENTAL
Intervention: Japanese version of the Social Adjustment Scale-Self Report (SAS-SR)
Number of subjects: 1944
Study: 10788200

Group type: EXPERIMENTAL
Intervention: Healthy labelled drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control information drink
Number of subjects: 0
Study: 9065105

Group type: EXPERIMENTAL
Intervention: Intravenous gamma‐globulin 1 gm/kg per week
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous gamma‐globulin 1 gm/kg per week with dexamethasone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Salvage treatment with 60 mg of prednisone per day
Number of subjects: 54
Study: 1326165

Group type: EXPERIMENTAL
Intervention: Short-term treatment with myelopid (MP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long-term treatment with myelopid (MP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Myelopid (MP) in patients with immunologic signs of pathological process activation
Number of subjects: 40